Figitumumab (previously CP-751871) is a monoclonal antibody targeting the  insulin-like growth factor-1 receptor that was investigated for the treatment of various types of cancer, for example adrenocortical carcinoma and  non-small cell lung cancer (NSCLC). 
This drug was being developed by
Pfizer, but they ceased development of the drug in January 2011 and has stopped its manufacture. 
Anti-cancer mechanism [ edit ]
Insulin-like growth factor 1 receptor role in cancer.
Clinical trials [ edit ]
The first phase III trial (for NSCLC) was suspended in December 2009 due to excess deaths
but others continued.   
It was to have been included in the I-SPY2
breast cancer trial. 
References [ edit ]
^ Statement On A Nonproprietary Name Adopted By The Usan Council - Figitumumab, American Medical Association.
^ Haluska, P; Worden, F; Olmos, D; Yin, D; Schteingart, D; Batzel, GN; Paccagnella, ML; De Bono, JS; et al. (2009). "Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma". Cancer chemotherapy and pharmacology. 65 (4): 765–773. doi: 10.1007/s00280-009-1083-9. PMC 2875253 . PMID 19649631.
^ Gualberto, A; Karp, DD (2009). "Development of the monoclonal antibody figitumumab, targeting the insulin-like growth factor-1 receptor, for the treatment of patients with non-small-cell lung cancer". Clinical Lung Cancer. 10 (4): 273–80. doi: 10.3816/CLC.2009.n.038. PMID 19632947.
^ "Cancer sufferer fears future without 'life-saver' drug". BBC News. July 2014.
^ Krauskopf, Lewis (29 December 2009). "Pfizer ends late-stage lung-cancer study". Reuters.
^ Clinical trial number for "Figitumumab Combined With Pegvisomant For Advanced Solid Tumors" at NCT00976508 ClinicalTrials.gov
^ Clinical trial number for "CP-751871 in Treating Women With Early-Stage Breast Cancer That Can Be Removed by Surgery" at NCT00635245 ClinicalTrials.gov
^ "Breast cancer study aims to speed drugs, cooperation". Reuters. March 2010.